Strategic Partnerships CDI has a history of collaboration with clinical trial providers (notably the Oct 2022 CliniOps partnership). This presents a sales opportunity to position CDI as a preferred GI diagnostics partner for CROs and trial sponsors seeking non-invasive, at-home breath tests for SIBO/IMO and related malabsorption conditions.

Clinical Trial Synergy Leverage CDI’s FDA-registered and ISO 13485-certified status to target contract research organizations and medical device integrators that require compliant diagnostic components, enabling end-to-end solutions for GI clinical studies and real-world evidence generation.

Breath Test Focus CDI’s core portfolio of non-invasive at-home breath tests for SIBO, IMO, and carbohydrate malabsorption positions it to cross-sell to GI clinics, primary care networks, and telemedicine platforms seeking convenient, patient-friendly diagnostic tools that can reduce in-clinic visits.

SMB Growth Potential With a reported revenue range of $1M–$10M and a lean employee base, CDI appears scalable through channel partnerships, distributor networks, and integrated digital marketing services, offering mid-market sales motion opportunities outside large national labs.

Tech & Reach CDI’s digital footprint and tech stack (WordPress, cloud services, marketing platforms) indicate readiness for outbound and inbound digital campaigns; sales initiatives can emphasize ease of integration with clinics’ workflows and data-management systems to streamline adoption of breath-testing programs.